5 Star

Demi hit her lowest weight of 7st in 2015. She said: “It got to the point where I would look in the mirror and I was unrecognisable.

“I was stepping on the scales and realising just how low the numbers were.”

She put on half a stone and convinced herself she had recovered, but was still desperately thin.

Anorexia stopped sociable Demi going out with friends, and soon she was only interacting with people through YouTube make-up tutorials.

She said: “I felt like they were like friends, because I was so isolated.

“It was the only time I wasn’t consumed by my eating disorder. I wanted to make videos and work as a make-up artist.

“But, at 18, something just snapped and I realised that if I wanted the life I was envisioning, I couldn’t do it if I was sick, or if I had to spend all day in bed – too thin or depressed to do anything.

“I felt like I was wasting my life.”

. .
. http://game-rapidshare.com/Delaune-brother-of-Pederzani-from-Riachão?Mckowngra=262
.
.
.
Cong councillor shot dead in Amritsar

Cong councillor shot dead in Amritsar

02 Jun 2018 | 8:50 PM
.

He presented data on a 17-year experience treating MS patients with the twice-weekly dosage of intramuscular IFNβ-1a at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting.

Baumhefner told MedPage Today that standard practice for experiencing breakthrough disease on interferon treatment is to switch them to another drug. Eighteen drugs have been approved for the treatment of MS, but around half became available within the past decade.

"The long-term side effects of these newer agents are not known, so it might be advantageous to keep many of these patients -- if they stabilize -- on a drug that has been proven to be safe for 25 years," Baumhefner said.

Several previous studies, including the PRISMS trial, have suggested a dose-response effect for IFN-β in the treatment of MS, but other studies have failed to show this. Baumhefner noted that prior studies have not addressed the strategy of doubling the IFN dosage and treatment schedule for IFN-treated patients with breakthrough disease.

A total of 107 MS patients were started on intramuscular IFNβ-1a at the MS clinic of the VA West Los Angeles Medical Center from 1995 to 2015, and 59 of these patients with breakthrough disease were switched to twice-weekly intramuscular IFNβ-1a. Fifty-two patients were followed for at least 2 years.

.